Idibell

Bellvitge research receives 1 million euros in PERIS 2016-2020 funding

Leave a Comment / Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Diabetes, Nutrition and endocrinological diseases , Difficult to Treat Infections and Antimicrobians Use , Health services research in cancer , Hematopoyetic and lymphoid tumors , Hereditary cancer , Infections of the Respiratoy Tract and in Immunocompromised Patients , Infectious disease and transplantation Program, Nursing, Systemic Diseases and Ageing  / By

The Department of Health has issued the final resolution of the first call for research grants linked to the Strategic Plan for Research and Innovation in Health (PERIS) 2016-2020. Researchers from the University Hospital of Bellvitge (HUB), the Catalan Institute of Oncology (ICO) and the University of Barcelona (UB) and their research projects, managed through […]

Bellvitge research receives 1 million euros in PERIS 2016-2020 funding Read More »

An epigenetic lesion could be responsible for acute T-cell leukemia

Leave a Comment / Uncategorised / By

Researchers from the Epigenetics and Cancer Biology Program (PEBC) led by Dr. Manel Esteller at the Bellvitge Biomedical Research Institute (IDIBELL) have discovered how an epigenetic lesion can lead to T-cell acute lymphoblastic leukemia. The article, published in the journal Leukemia, leader in the field of hematology, correlates the lesion with the activation of a

An epigenetic lesion could be responsible for acute T-cell leukemia Read More »

The IT-LIVER European consortium unveils new TGF-beta functions in liver cancer

Leave a Comment / TGF-beta and cancer / By

Recent research results from the TGF-beta and cancer research group at the Bellvitge Biomedical Research Institute (IDIBELL), within IT-Liver, a collaborative European action among several research groups led by Dr. Isabel Fabregat, provide a better understanding of the role of the TGF-beta cytokine in liver cancer. Their work, published in Cancer Letters, shows how the

The IT-LIVER European consortium unveils new TGF-beta functions in liver cancer Read More »

The research in Neurofibromatosis receives again the support of the city of Manlleu

Leave a Comment / Uncategorised / By

The 2nd floor of the parking under Manlleu Square was filled with people, on February 12, to enjoy the Solidarity Underground Festival for the Neurofibromatosis research, organized by the Health Center Fitness Spa and Health Fina 67 study, jointly with the Catalan Association of Neurofibromatosis (ACNefi). During the day, which was very successful, workshops, a

The research in Neurofibromatosis receives again the support of the city of Manlleu Read More »

ICS visits IDIBELL

Leave a Comment / Uncategorised / By

Last Thursday, March 16th, an official visit of representatives of the Scientific and Research Directorate of the Catalan Health Institute (ICS) took place at the Bellvitge Biomedical Research Institute (IDIBELL). This visit is part of the programme that the Scientific and Research Directorate of ICS carries out to get involved with its linked Health Research

ICS visits IDIBELL Read More »

Cryopreserved orthoxenografts broaden the scope of single cell sequencing technologies

Leave a Comment / Tumor and stromal chemoresistance  / By

Researchers from Bellvitge Biomedical Research Institute (IDIBELL) – Catalan Institute of Oncology (ICO), led by Dr. Alberto Villanueva, and Bellvitge University Hospital (Dr August Vidal) have contributed to a study carried out by Centro Nacional de Análisis Genómico (CNAG-CRG) that has substantially broadened the applicability of single cell genomics by combining cell and tissue cryopreservation

Cryopreserved orthoxenografts broaden the scope of single cell sequencing technologies Read More »

Scroll to Top